Clinical trials: Radioligand
Drug Resistance
(18F)FCWAY and the Blood-Brain Barrier
Background: The blood-brain barrier helps protect the brain from infections and toxins in the blood stream. But it can also prevent certain drugs from reaching the brain to treat diseases or other problems.
- Trial name
- NCT01386476
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Parkinson Disease
Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers
This study investigates the initial safety profile of [18F]P17-059 in healthy volunteers including dosimetry determination, and compares regional brain uptake and kinetics of [18F]P17-059 in Parkinson's disease patients with…
- Trial name
- NCT03903549
- Testing
- [18F]P17-059
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Five Eleven Pharma, Inc.
Alzheimer Disease, Healthy Volunteers
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
The overall goal of this imaging trial is to evaluate [18F]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).
- Conditions
- Alzheimer Disease, Healthy Volunteers, Progressive Supranuclear Palsy
- Trial name
- NCT03058965
- Testing
- [18F]MNI-958, [18F]Florbetapir, DaTscan
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Depression
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)
Background: The brain enzyme phosphodiesterase-4D (PDE4D) may affect thinking and depression. Drugs with some radioactivity can attach to enzymes and be seen on a scan.
- Trial name
- NCT03861000
- Testing
- [C-11]T-1650, BPN14770
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects
The purpose of this trial is to conduct an assessment of brain nociceptin/orphanin FQ peptide (NOP) receptor occupancy (RO) in healthy subjects.
- Trial name
- NCT01404091
- Testing
- LY2940094
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BlackThorn Therapeutics, Inc.
Healthy Volunteer, Alzheimer Disease
Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain
The overall goal of this imaging trial is to evaluate [18F]PI-2620, a tau targeted positron emission computed tomography radioligand, in individuals with tauopathies and healthy volunteers (HV).
- Conditions
- Healthy Volunteer, Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease
- Trial name
- NCT03510572
- Testing
- [18F]PI-2620
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Huntington Disease
iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626
This is a FIH (first-in-human) adaptive PET (Positron Emission Tomography) imaging study to explore the binding and kinetic properties of two potential mutant huntingtin (mHTT) radioligands; [¹¹C]CHDI-00485180-R and…
- Trial name
- NCT03810898
- Testing
- Radioligand [¹¹C]CHDI-00485180-R, Radioligand [¹¹C]CHDI-00485626
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CHDI Foundation, Inc.
Dementia
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
Background: Aging-related progressive neurological disorders include frontotemporal dementia, Lou Gehrig s disease, and Alzheimer s disease. Little is known about what causes these disorders. Brain inflammation may be involved.
- Trial name
- NCT03958630
- Testing
- 11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
COVID Long-Haul
Long COVID-19 [11C]CPPC Study
The goal of this study is to evaluate the safety of using the [5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide] ([11C]CPPC) radiotracer in positron emission tomography (PET) imaging of…
- Trial name
- NCT06223971
- Testing
- [11C]CPPC Injection
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Parkinson Disease (PD), MSA - Multiple System Atrophy
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of [11C]MODAG-005, an investigational positron emission tomography/computed tomography (PET/CT) radioligand…
- Conditions
- Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
- Trial name
- PIOSA (NCT07640542)
- Testing
- [11C]MODAG-005
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Brain Distribution of [11C]AZ12807110 and AZD5213
Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration
The purpose of this study is to investigate features of radioligand [11C]AZ12807110 and how much AZD5213 displaces radioligand from histamine receptors when given together.
- Trial name
- NCT01194986
- Testing
- [11C]AZ12807110, AZD5213
- Where
- Sweden
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Maximum Diagnostic Mass of [18Fluor]AZD4694
An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease
In this study different mass of the radioligand AZD4694 will be given to patients with Alzheimer's Disease and healthy volunteers to evaluate wich Mass of AZD4694 that gives the best opportunities for following disease progress…
- Trial name
- NCT01325402
- Testing
- [18Fluor]AZD4694
- Where
- 2 sites in Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alcohol Dependence
A Study of Brain Receptor Occupancy in Healthy Subjects
To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.
- Trial name
- NCT01232439
- Testing
- opioid receptor kappa antagonist
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
[18F]PBR111 and Microglial Activation in Multiple Sclerosis
This is a study aimed to characterize [18F]PBR111 as an in vivo marker of microglial activation in Multiple Sclerosis. Regional binding of [18F]PBR111 will be quantified with PET in the brain of up to 24 patients with multiple…
- Trial name
- NCT01428505
- Testing
- [18F]PBR111
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Progressive Supranuclear Palsy, Alzheimer Disease
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
The overall goal of this imaging trial is to evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.
- Conditions
- Progressive Supranuclear Palsy, Alzheimer Disease, Healthy Volunteers
- Trial name
- NCT03080051
- Testing
- [18F]MNI-952, [18F]Florbetapir
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Healthy
A Study of LY3857210 in Healthy Participants
The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand [18F]-LY3818850 in healthy participants.
- Trial name
- NCT05292040
- Testing
- LY3857210
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP)
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
The overall goal of this imaging trial is to characterize [18F]MNI-815, a PET radioligand for imaging Tau.
- Conditions
- Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
- Trial name
- NCT02531360
- Testing
- [18F]MNI-815 (MNI-815)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Pharmacokinetics, Adult
Evaluation of a Novel PET Radioligand to Image OGA
Background: O-GlcNAcase (OGA) is a brain enzyme. It may play a role in brain disorders like Alzheimer s disease. Researchers want to see if a new drug can be used with positron emission tomography (PET) scans to show OGA better.
- Trial name
- NCT03632226
- Testing
- 18F-OGA-1
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)